GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (STU:ET80) » Definitions » Shiller PE Ratio

AEterna Zentaris (STU:ET80) Shiller PE Ratio : (As of Jun. 07, 2024)


View and export this data going back to 1995. Start your Free Trial

What is AEterna Zentaris Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


AEterna Zentaris Shiller PE Ratio Historical Data

The historical data trend for AEterna Zentaris's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEterna Zentaris Shiller PE Ratio Chart

AEterna Zentaris Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

AEterna Zentaris Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of AEterna Zentaris's Shiller PE Ratio

For the Biotechnology subindustry, AEterna Zentaris's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AEterna Zentaris's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AEterna Zentaris's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where AEterna Zentaris's Shiller PE Ratio falls into.



AEterna Zentaris Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

AEterna Zentaris's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, AEterna Zentaris's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-4.361/126.2576*126.2576
=-4.361

Current CPI (Mar. 2024) = 126.2576.

AEterna Zentaris Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -662.400 99.473 -840.759
201409 -1,552.000 99.394 -1,971.459
201412 643.934 98.367 826.512
201503 -1,255.716 99.789 -1,588.784
201506 -1,216.215 100.500 -1,527.918
201509 -593.406 100.421 -746.076
201512 -92.626 99.947 -117.009
201603 -33.226 101.054 -41.513
201606 -63.190 102.002 -78.217
201609 -54.351 101.765 -67.432
201612 -69.204 101.449 -86.128
201703 -28.985 102.634 -35.657
201706 -16.020 103.029 -19.632
201709 -51.179 103.345 -62.526
201712 0.845 103.345 1.032
201803 70.557 105.004 84.838
201806 -13.696 105.557 -16.382
201809 -12.855 105.636 -15.364
201812 -28.128 105.399 -33.695
201903 -26.550 106.979 -31.334
201906 0.885 107.690 1.038
201909 -1.816 107.611 -2.131
201912 -3.600 107.769 -4.218
202003 3.620 107.927 4.235
202006 -13.320 108.401 -15.514
202009 -1.698 108.164 -1.982
202012 -1.719 108.559 -1.999
202103 -1.680 110.298 -1.923
202106 -1.428 111.720 -1.614
202109 -1.360 112.905 -1.521
202112 -2.230 113.774 -2.475
202203 -1.961 117.646 -2.105
202206 -3.292 120.806 -3.441
202209 -2.828 120.648 -2.959
202212 -9.667 120.964 -10.090
202303 -3.278 122.702 -3.373
202306 -1.920 124.203 -1.952
202309 -3.186 125.230 -3.212
202312 -4.255 125.072 -4.295
202403 -4.361 126.258 -4.361

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AEterna Zentaris  (STU:ET80) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


AEterna Zentaris Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of AEterna Zentaris's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


AEterna Zentaris (STU:ET80) Business Description

Traded in Other Exchanges
Address
222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7
AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.

AEterna Zentaris (STU:ET80) Headlines

No Headlines